Dashboard
1
With ROE of 6.76%, it has a very attractive valuation with a 0.72 Price to Book Value
- Over the past year, while the stock has generated a return of 14.80%, its profits have risen by 39.4% ; the PEG ratio of the company is 0.3
- At the current price, the company has a high dividend yield of 2.7
Stock DNA
Pharmaceuticals & Biotechnology
CNY 21,656 Million (Large Cap)
11.00
NA
2.69%
-0.03
6.76%
0.72
Revenue and Profits:
Net Sales:
494 Million
(Quarterly Results - Jun 2025)
Net Profit:
762 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.89%
0%
0.89%
6 Months
16.02%
0%
16.02%
1 Year
2.88%
0%
2.88%
2 Years
17.15%
0%
17.15%
3 Years
21.9%
0%
21.9%
4 Years
13.76%
0%
13.76%
5 Years
8.81%
0%
8.81%
Jilin Aodong Pharmaceutical Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-1.94%
EBIT Growth (5y)
-235.95%
EBIT to Interest (avg)
-0.75
Debt to EBITDA (avg)
0.12
Net Debt to Equity (avg)
-0.01
Sales to Capital Employed (avg)
0.10
Tax Ratio
100.00%
Dividend Payout Ratio
37.94%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.22%
ROE (avg)
7.40%
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
0.72
EV to EBIT
-91.68
EV to EBITDA
6208.06
EV to Capital Employed
0.71
EV to Sales
9.06
PEG Ratio
0.27
Dividend Yield
2.69%
ROCE (Latest)
-0.78%
ROE (Latest)
6.76%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
494.10
543.10
-9.02%
Operating Profit (PBDIT) excl Other Income
42.40
7.00
505.71%
Interest
14.20
14.80
-4.05%
Exceptional Items
99.40
-205.60
148.35%
Consolidate Net Profit
762.00
385.50
97.67%
Operating Profit Margin (Excl OI)
-25.70%
-97.00%
7.13%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -9.02% vs -30.74% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 97.67% vs -31.58% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,573.30
3,402.70
-24.37%
Operating Profit (PBDIT) excl Other Income
99.50
364.40
-72.69%
Interest
94.50
146.20
-35.36%
Exceptional Items
-187.00
-113.70
-64.47%
Consolidate Net Profit
1,519.20
1,444.30
5.19%
Operating Profit Margin (Excl OI)
-54.00%
36.70%
-9.07%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -24.37% vs 20.43% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 5.19% vs -19.81% in Dec 2023
About Jilin Aodong Pharmaceutical Group Co., Ltd. 
Jilin Aodong Pharmaceutical Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






